Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Innovation and Product Development news
(page 4)
17 July 2026
SONATRACH and Siemens Energy sign MoU on maintenance, green hydrogen and compression
MoU to co-develop maintenance and repair solutions, training, digitalisation and predictive maintenance, and to support local green steel and green ammonia value chains.
17 July 2026
European Commission Electrification Action Plan and ETS review
Sets a 46% electrification target by 2040, reforms the EU ETS to drive investment and stability, and mobilises funding and regulatory measures to lower electricity costs and speed grid rollout.
17 July 2026
GSK updates CALM-1 and CALM-2 camlipixant phase III results
50 mg twice daily cut 24‑hour coughs in CALM‑1; CALM‑2 and the 25 mg dose failed primary/secondary endpoints, prompting halt of RCC development.
16 July 2026
GS Caltex completes 2026 first-half turnaround at Yeosu Complex using digital and AI
Nine-unit, ~60-day maintenance used digital and AI tools to speed inspections, clean heater tubes, monitor safety and reinforce safety leadership across operations.
16 July 2026
Boehringer Ingelheim: BI 3034701 triple GLP‑1/GIP/NPY2 agonist enters Phase II
Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
16 July 2026
Alfen and CATL partner on 5 GWh sodium‑ion storage deployment in Europe
Joint plan to deploy 5 GWh of sodium‑ion battery storage across Europe to cut costs, diversify supply and reduce exposure to lithium price swings.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
16 July 2026
Takeda: Zasocitinib achieves high, consistent clearance at hard-to-treat psoriasis sites
Phase 3 secondary data show ~75% scalp and ~70% palmoplantar clearance at week 16; significant nail improvement; responses sustained to week 24; common AEs: URTI, nasopharyngitis, acne.
16 July 2026
Eastman’s Kingsport methanolysis plant hosts EPA officials
EPA leaders toured a methanolysis unit that processes >250 million lb/yr of polyester waste and reports 20–30% lower GHGs versus fossil-based plastic production.
16 July 2026
Infinium supplies eNaphtha for On's CleanCloud EVA midsole
CO₂‑derived eNaphtha used as a drop‑in feedstock to produce EVA midsoles at commercial scale; shipments began in 2024, ISCC PLUS chain‑of‑custody, and more than one million pairs produced.
16 July 2026
Lilly to acquire AtaiBeckley to add rapid-acting neuroplastogen pipeline
Adds BPL-003 (mebufotenin benzoate intranasal) and VLS-01 (DMT buccal); upfront $6.75/share plus up to $2.50/share CVR tied to development, regulatory and DEA-rescheduling milestones.
16 July 2026
Merck’s LIPFENDRA — first FDA‑approved once‑daily oral PCSK9 inhibitor
Oral macrocyclic peptide enlicitide (20 mg) lowers LDL-C ~56–59% at week 24 in Phase 3 trials; approved as adjunct to diet and exercise for adults with hypercholesterolemia, including HeFH.
16 July 2026
Air Liquide invests >160M USD in Arizona for ultra‑pure gases for advanced chips
Arizona plant to supply ultra-high-purity gases for advanced-chip fab expansion using on-site low-carbon hydrogen production and CO2 capture.
15 July 2026
Repsol, Toyota, BMW and Bosch pilot cars on 100% renewable gasoline
Six-month Spanish trial uses existing cars, 100% renewable gasoline and digital tracking to demonstrate drop-in fuel scalability without new vehicles or infrastructure.
15 July 2026
Novo Nordisk wins EU authorisation for Wegovy pill and single‑dose 7.2 mg pen
OASIS data showed ~17% mean weight loss and ~1 in 3 reached ≥20%; safety comparable to injectable semaglutide; wider roll‑out planned in H2 2026.
15 July 2026
PureCycle, Mitsui and RM TOHCELLO to bring recycled PP to BOPP film in Japan
Aiming to introduce recycled polypropylene into BOPP flexible packaging; pilot runs successful and a commercial agreement is targeted for 2027 ahead of shipments subject to import clearance.
15 July 2026
DuPont launches end-to-end Direct Lithium Extraction portfolio
End-to-end DLE suite of 20+ products across sorbents, membranes and ion-exchange resins, plus lab testing, modeling and piloting to tailor flowsheets to varied brine chemistries.
15 July 2026
Merck to present daily, weekly and monthly HIV data at AIDS 2026
Late‑breakers include Week 48 results for once‑weekly islatravir+lenacapavir and Week 24 data for islatravir+ulonivirine; once‑monthly PrEP trials are enrolling.
15 July 2026
GSK completes Nuvalent acquisition, adds three NSCLC assets
Adds three NSCLC assets including two under FDA review for ROS1 and ALK with target decisions later this year; expected 2026 launches; deal valued at ~$10.6bn.
15 July 2026
Johnson & Johnson Q2 2026 results and raises 2026 outlook
Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
15 July 2026
Merck KEYTRUDA improves PFS vs platinum chemotherapy in dMMR endometrial cancer (Phase 3)
Phase 3 trial finds pembrolizumab monotherapy improves PFS versus platinum doublet chemotherapy in dMMR advanced or recurrent endometrial cancer.
15 July 2026
Axens to build France’s first industrial-scale Jetanol™ SAF unit
50,000 t/y SAF plant using advanced bioethanol and Jetanol™ technology; production targeted for 2030 to boost French/European SAF supply and meet ReFuelEU targets.
15 July 2026
Roche: FDA grants Priority Review for Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy
Priority Review follows MAJESTY phase III showing 36.9% complete remission at two years vs 5.7% with tacrolimus; FDA decision expected by Nov 2026.
14 July 2026
Genentech’s Gazyva (obinutuzumab) granted FDA priority review for primary membranous nephropathy
FDA granted priority review for obinutuzumab in pMN after Phase III MAJESTY showed markedly higher complete remission vs tacrolimus; FDA decision expected Nov 2026.
14 July 2026
Velocys launches AlphaCore 400 to extend microchannel FT into larger SAF projects
New higher-capacity microchannel reactor doubles capacity vs AlphaCore 200 to enable larger, lower-cost SAF and synthetic-fuel projects.
14 July 2026
Evonik and evitria launch eviCHO CHO‑K1 transient expression kit
Ready-to-use CHO‑K1 transient expression kit simplifies lab workflows and speeds consistent protein production for early-stage biologics research.
14 July 2026
Topsoe and Sasol license G2L SAF technology to Allied Biofuels for Uzbekistan plant
License and engineering deal to supply G2L eSAF and bio‑SAF technology for a Khorezm plant producing about 300,000 t SAF/eSAF annually; FID 2027, commercial ops targeted 2030.
14 July 2026
Acelen Renewables and Bunge sign five-year certified soybean oil supply for SAF and HVO
Five-year supply of 300,000 t/yr certified soybean oil (total >1 Mt) for SAF and renewable diesel at a Bahia biorefinery due to start operations in 2029.
13 July 2026
Rivus Batteries raises €2 million to scale critical‑mineral‑free flow battery chemistry
€2m seed plus €2m in grants to scale an organic, critical‑mineral‑free flow battery electrolyte compatible with commercial flow battery hardware.
13 July 2026
Eni and BMW Group agree use of Enilive HVOlution for BMW corporate fleets
Corporate fleets to run on 100% HVO diesel from renewable feedstocks with per-vehicle traceability and station coverage across Italy, Germany and Austria.
13 July 2026
BASF adds three REDcert² biomass‑balanced additives for architectural coatings
Three REDcert²‑certified biomass‑balanced additives enable lower product carbon footprint for architectural coatings while retaining existing performance and formulation compatibility.
← Previous
Next →
